Astellas Updates on European Union Marketing Authorization Application for Avacincaptad Pegol (ACP)
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) has announced the withdrawal of its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution…
Biogen Shares Positive Phase 2 Results for Felzartamab in IgA Nephropathy at ASN Kidney Week 2024
Biogen Inc. (Nasdaq: BIIB) shared full results from its Phase 2 IGNAZ study on felzartamab, an investigational anti-CD38 monoclonal antibody, for IgA nephropathy (IgAN) treatment. Data revealed significant reductions in…
Dr. Reddy’s Recognized by Science Magazine as a Top 20 Global Pharma Employer for the Third Year in a Row
Dr. Reddy’s Laboratories Ltd. has been recognized as one of the top employers in the 2024 Top Biotech and Pharma Employers Survey conducted by Science magazine, marking the company’s third…
enGene Secures $60 Million in Private Placement Financing
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, has announced an agreement to sell 6,758,311 of its common shares at a price of $8.90 per share. This financing…
Felix Health Launches First National Menopause Show for Women in Perimenopause and Beyond
Felix Health, a virtual care provider dedicated to helping Canadians manage their everyday health needs, is excited to be the presenting sponsor of the National Menopause Show. Set to attract…
LabGenomics USA Finalizes Acquisition of IMD CLIA Labs
LabGenomics USA has successfully acquired Integrated Molecular Diagnostics (IMD) CLIA labs, increasing its total number of CLIA-certified labs in the U.S. to four. This acquisition enhances LabGenomics’ strategic growth and…
Maze Therapeutics Announces Positive Phase 1 Data for MZE829 in Treating APOL1 Kidney Disease
Maze Therapeutics, a clinical-stage biopharmaceutical company focused on leveraging human genetics to create innovative small molecule precision medicines for common diseases, has announced promising results from the Phase 1 clinical…
BioHub Maryland Launches Biopharma Workforce Training Center in Montgomery County’s Life Sciences Corridor
BioHub Maryland, an initiative aimed at accelerating the life sciences sector in the state, officially opened its new biopharmaceutical workforce training center on October 24 at 9808 Medical Center Drive…
Evecxia Therapeutics Successfully Completes Pre-IND Meeting with FDA on EVX-101 Development for Depression
Evecxia Therapeutics has announced the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) Division of Psychiatry, Office of Neuroscience, Center for…
Lilly’s EBGLYSS™ Achieves Skin Clearance and Itch Relief in Atopic Dermatitis Patients
Eli Lilly and Company has reported encouraging findings regarding its treatment EBGLYSS, showing significant improvements in skin condition and itch relief for patients suffering from moderate-to-severe atopic dermatitis (eczema) who…
Vertex Provides Kidney Program Updates at ASN Kidney Week Congress
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced updates on its kidney disease pipeline, which includes treatments for IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and APOL1-mediated kidney disease (AMKD). These updates…
Every Day Without Vision Is One Too Many: Tackling the Impact of Eye Diseases
Losing your sight can profoundly impact your life, affecting everything from connections to experiences. Our eyes serve as a window to the world, and when vision is lost, it can…